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Abstract
In myasthenia gravis (MG) an autoimmune response against
muscle acetylcholine receptor (AChR) occurs. Embryonic
muscle AChR contains a y subunit, substituted in adult muscle
by a homologous e subunit. Antibodies and CD4 + cells specific
for embryonic AChR have been demonstrated in MG patients.
We identified sequence segments of the human y subunit
forming epitopes recognized by four embryonic AChR-specific
CD4' T cell lines, propagated from MG patients' blood by
stimulation with synthetic peptides corresponding to the hu-
man -y subunit sequence. Each line had an individual epitope
repertoire, but two 20-residue sequence regions were recog-
nized by three lines of different HLA haplotype. Most T epi-
tope sequences were highly diverged between the y and the
other AChR subunits, confirming the specificity of the T cells
for embryonic AChR. These T cells may have been sensitized
against AChR expressed by a tissue other than innervated skel-
etal muscle, possibly the thymus, which expresses an embry-
onic muscle AChR-like protein, containing a y subunit. Several
sequence segments forming T epitopes are similar to regions of
microbial and /or mammalian proteins unrelated to the AChR.
These findings are consistent with the possibility that T cell
cross-reactivity between unrelated proteins ("molecular mim-
icry"), proposed as a cause of autoimmune responses, is not a
rare event. (J. Clin. Invest. 1992. 90:1558-1567.) Key words:
embryonic acetylcholine receptor * myasthenia gravis * T epi-
topes
Introduction
In myasthenia gravis (MG) 1 an autoimmune response against
muscle nicotinic acetylcholine receptor (AChR) occurs ( 1-4).
Anti-AChR T helper (CD4', Th) cells can be propagated in
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1. Abbreviations used in this paper: AChR, muscle nicotinic acetylcho-
line receptor; APC, antigen presenting cells; FBAChR, fetal (embry-
onic) bovine muscle AChR; y Pool, a pool of synthetic peptides corre-
sponding to the complete sequence ofhuman muscle AChR y subunit;
MG, myasthenia gravis; TCM, tissue culture medium; Th, anti-AChR
T helper cells.
vitro from the blood and thymus ofMG patients (5-9). They
stimulate the production ofanti-AChR antibodies in vitro (10)
and recognize the AChR in association with HLA-DR mole-
cules (I I). Because Th cells recognize denatured AChR (6),
they can be propagated in vitro using synthetic sequences ofthe
AChR to yield polyclonal CD4+ T cell lines enriched in AChR-
specific T cells (7, 12, 13).
The AChR is a complex protein, formed in nonneuronal
tissue by four homologous subunits (14). Skeletal muscle
AChR exists in two forms, whose expression is developmen-
tally regulated ( 15-17). An embryonic AChR is expressed be-
fore innervation occurs, whereas a different AChR is expressed
by adult innervated muscle ( 15-17). Both AChRs contain two
a, one j3, and one 5 subunits ( 15). Embryonic AChR also con-
tains a Sy subunit, substituted in adult AChR by a homologous E
subunit ( 15-17). Adult mammalian thymus expresses a pro-
tein similar or identical to embryonic muscle AChR, contain-
ing a y subunit in addition to a, fl, and S subunits ( 18).
We previously propagated Th cell lines specific for embry-
onic AChR from the blood of MG patients, using a pool of
overlapping synthetic peptides corresponding to the complete
sequence ofthe human y subunit ( 19). This finding has ramifi-
cations for the pathogenesis of MG, because it has been pro-
posed that the anti-AChR sensitization in MG may originate
within the thymus (20): the existence of MG patients of Th
cells specific for embryonic AChR strongly supports this hy-
pothesis. Further, antibodies specific for embryonic muscle
AChR are frequently present in MG patients (21, 22). A study
that used junctional (i.e., adult) and extrajunctional (i.e., em-
bryonic) rat muscle AChRs indicated that antibodies in MG
patients recognized determinants either unique to embryonic
AChR or common to both forms, never determinants unique
to adult AChR (21 ). Finally, a case ofMG has been described
where the antibodies recognized onlythe embryonic form ofrat
muscle AChR (23). The thymus ofMG patients is frequently
hypertrophic or it contains a thymoma (24), and it contains
anti-AChR Th and B cells (8, 25). Thymectomy is beneficial
for the evolution of MG and is a staple in the treatment of
MG (26).
In this study we sought to identify the sequence segments of
the human AChR y subunit that form epitopes recognized by
autoimmune CD4+ cell lines specific for embryonic AChR
( 19), propagated from fourMG patients ofdifferent HLA-DR
type, by challenging the lines with individual overlapping pep-
tides, spanning the complete sequence of the human AChR y
subunit. For the sequence regions found to contain T epitopes,
we searched for similarities with unrelated proteins to deter-
mine if the results reported here are compatible with the pro-
posed origin of autoimmune responses from mechanisms of
molecular mimicry between self components and microbial
proteins (27).
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Table I. Characteristics ofthe Myasthenic Patients
Patient
No. Age Sex Disease class* Ab titer Thymectomy Treatment HLA haplotypet
yr nM
1 33 M 2 59.0 + Prednisone Aw24, A26, B8, Bw58
DRw15 (2)-Dw2, DRw1 1 (5), DRw52, Dw25
DQw6 (1), DQw7 (3)
2 73 M 2 3.55 - Prednisone A2, A29, B7, Bw44
DR2, DR7
DQw1, DQw2
3 33 F 2 0.0 + Prednisone A2, A3, Bw35, Bw22
DRwI (1), DRw14 (6), Dw9, DRw52, Dw25
DQw5 (1)
4 46 F 2 2.31 + Prednisone Al, B7, Bw44
DRw15 (2)-Dw2, DR4 (Dw4), DRw53
DQw6 (wI), DQw7 (w3)
5 57 M 2 3.22 + Prednisone Al, A29, B8, Bw44
DR3, DR7
* Classified as described in reference 28. Determined by restriction fragment length polymorphism (69) and (for the DR4 subtypes) by oligo-
nucleotide hybrydization for patients 1, 3, and 4 and by microcytotoxicity (70) for patients 2 and 5.
Methods
Patients and T cell lines. The clinical characteristics of the myasthenic
patient donors of the anti-AChR -y subunit T cell lines, classified ac-
cording to a modification of the Osserman classification (28), their
serum anti-AChR antibody titer (measured as described in reference
29), and HLA haplotype are summarized in Table I. Propagation and
characterization of the CD4+ T lines are described in detail in (19).
Briefly, the lines were propagated from PBMCs by cycles ofstimulation
with a pool of synthetic peptides ([y Pool] 1 gg/ml of each peptide)
corresponding to the complete sequence of human y subunit (as re-
ported in reference 30) for 2 d, followed by stimulation with IL-2 (10
U/ml) for 5 d, using as antigen presenting cells (APC) irradiated
(4,000 rad) HLA-DR-matched PBMC for the lines from MG patients
and irradiated autologous PBMC for the control lines. Autologous or
DR-matched PBMC are equally good APC for propagation of anti-
AChR Th lines (11, 31), which are DR restricted (11). The cell pheno-
type of the T lines, determined by FACS analysis (7), was uniformly
CD3+, CD4+, CD8-. They could be propagated for several months
and specifically recognize embryonic AChR (19 and below) whereas
they cross-react to a very small extent or not at all with adult muscle
AChR (19). Propagation of T cell lines using the -y pool was also at-
tempted from six healthy subjects, four of which controls (1-4) were
those used in the study reported in reference 19. T lines could be propa-
gated for a short time (30-40 d) from controls 3, 4, and 5.
CD8+ Tcells depletion ofPBMC. For patients 3 and 4 we also tested
the response to the y subunit synthetic sequence of unselected CD8 + -
depleted, CD4+-enriched T cells from peripheral blood. CD8+ T cell
depletion ofPBMC was done using mouse anti-CD8 antibody (OKT8;
Ortho Pharmaceutical, Raritan, NJ) and paramagnetic beads coated
Table II. Amino Acid Composition ofSynthetic Peptides Forming Epitopes Recognized by the T Cell Lines
Hy39-49 H-y75-94 Hy 135-194 Hy297-312 Hy321-340 Hy336-355 Hy470-489
Expected Found Expected Found Expected Found Expected Found Expected Found Expected Found Expected Found
D,N 3 3 2 2.2 3 3.1
E,Q 3 3 1 1.3 3 3.4
S 2 2.1 1 1 3 3
G
H
I 1.3 2 2.2
2 1.9 1 1.1 2 1.8
I 1.2
2 2.1 1 0.8
1 1.3
I 1.1 4 4.1
1 1
1 0.9 1 0.8
5 4 3 2.5
2 2.5 2 2.2
1 1.1 3 3.4
2 2.1 1 1.0
1 1.2
1 1 1 1
1 1.7 4 4.7 2 2.3
1 1.1
I 1.1 3 2.9
1 1.2 2 2.2 2 2
6 4.9 3 3
1 1
1 1 1 0.8
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with goat anti-mouse Ig antibody (Advanced Magnetics Inc., Cam-
bridge, MA) (7). The CD8+-depleted, CD4+-enriched cells thus ob-
tained (referred to as CD4+-enriched cells) were consistently 45-55%
ofthe starting PBMC. The cellular composition ofthe CD4+-enriched
cells was determined in four pilot experiments by FACS analysis (FAC-
Star; Becton Dickinson, Mountain View, CA), using phycoerythrin-
conjugated Leu 2 (anti-CD8), Leu 3 (anti-CD4), and Leu 4 (anti-
CD3) antibodies (Becton Dickinson) (7), and was (n = 4): T cells
(CD3+), 61.4+15%; CD4' cells, 55.5+14.3%; CD8' cells, 0.5±0.1%.
Peptide synthesis and characterization. 35 peptides, 11-20 residues
long and corresponding to the complete sequence ofthe human AChR
y subunit (30), were synthesized (32). They overlapped each other by
approximately five residues to reduce the chance of missing epitopes
"split" between peptides. The codes ofthe peptides included the letters
Hy for human y subunit and two numbers indicating the position on
the y subunit sequence of the first and the last residue of the peptide.
They corresponded to the sequence segments ofthey subunit indicated
along the abscissa of Fig. 2. HPLC analysis ofthe peptides (19) using a
C18 column (Ultrasphere ODS) consistently showed one main peak of
optical density. Amino acid composition analysis (33) yielded an ex-
cellent correspondence between experimental and expected values for
all peptides. The amino acid composition ofthe peptides containingTh
epitopes is reported in Table II. Sequence and purity of randomly se-
lected peptides from different syntheses were verified by gas-phase se-
quencing (Applied Biosystems, Foster City, CA). Only the expected
sequence was found. Contaminating sequences (shorter homologous
peptides missing one or more residues because of incomplete cou-
pling), when detectable, accounted for 5-15% of the total signal.
Purification ofAChRsfrom bovine muscle. Fetal (embryonic) bo-
vine muscle AChR (FBAChR) was purified from fetuses 8-12-in
long (34).
Microproliferation assay. T line cells (blasts) (2 x 105/ml in tissue
culture medium [TCM]: RPMI 1640 with 10% heat-inactivated hu-
man AB serum, 2 nM L-glutamine, 100 U/ml penicillin, and 50 4g/ml
streptomycin) and autologous (for control lines) or HLA-DR-
matched APC (2 X 106 in TCM) were plated in triplicate in 96-round-
bottom-well plates (100Ig of blast cells and 100,ul ofAPC) and stimu-
lated with one ofthe following antigens: y pool (0.05, 0.1, 0.5, 1, and 5-
Mg of each peptide/ml), PHA (10 Ag/ml; Wellcome Reagent Ltd.,
Beckenham, UK), FBAChR (5, 2.5, and 1.25,ug/ ml), or each individ-
ual synthetic peptide (10 ug/ml). Triplicate wells with blasts alone
were seeded as controls. Blanks were wells with blasts plus APC and/or
wells with blasts and APC plus 10 ,g/ml of a 19-residue synthetic
peptide unrelated to the human y subunit (peptide E73, corresponding
to residues 1-19 of the major intrinsic protein of bovine lens [35]).
After 24 h the cells were labeled for 16-20 h with [3H]thymidine (1
,qCi/well, specific activity 6.7 Ci/mmol; Amersham Corp., Arlington
Heights, IL), harvested (Titertek multiple harvester; Skatron Inc.,
Sterling, VA) and the incorporation of [3H]thymidine was measured
by liquid scintillation. Similar microproliferation assays were carried
out (for patients 3 and 4) with CD4+-enriched cells, using 1 X 105
cells/ well and labeling with [3H]thymidine after 120 h.
Search for sequence similarities between y subunit sequence seg-
ments containing T epitopes and unrelated proteins. The protein se-
quences contained in the databases PIR 29 and Swiss-Prot 19 were
searched for sequence similarities with the segments of the Y subunit
sequence found to contain T epitopes (y3O-49, y6O-79, y75-94,
,y135-154, yI65-184, y297-312, y321-340, y336-355, y4l1-430,
y470-489, and y476-495, see Results), using the program FASTDB
(version 5.4) (36) of the Intelligenetics suite (IG, Inc., Mountain
View, CA).
Results
The CD4+ lines propagated from MG patients with the syn-
thetic by pool are AChR specific. The specificity of the T cell
lines for the AChR was tested by their ability to recognize
FBAChR (Fig. 1). AChR from bovine muscle is a good substi-
tute for the exceedingly scarce human muscle AChR because it
can be purified in sufficient amounts (34) and is highly homolo-
gous to human AChR ( 14, 30, 37): the bovine y subunit is 92%
identical to the human y subunit (30, 37). Lines 2, 3, and 4
responded to 5 ,g/ml ofFBAChR at least as strongly as to the
highest concentration of y pool used (5 ,ug/ml ofeach peptide)
whereas the response to FBAChR of line 1, although signifi-
cant, was consistently lower than the response to the y pool.
Sequence segments ofthe human y subunit recognized by
CD4' linesfrom MG patients. The segments of the y subunit
sequence forming epitopes recognized by the CD4' cell lines
were identified by challenging the lines with the individual syn-
thetic peptides present in the y pool. The lines were tested for
reactivity to the individual synthetic peptides as soon as a satis-
factory enrichment in reactivity to y pool was achieved, i.e.,
when the response ofthe T cell lines to the hy pool in micropro-
liferation assays was comparable to the response to PHA (Fig.
1), which occurred after 3-4 wk of culture, and every 1-2 wk
during the first 5 mo of propagation of the lines, to verify the
consistency of the recognition and detect any clonal enrich-
ment/loss. The lines frequently had a high rate of basal cell
proliferation, which frequently occurs when T blasts are used
(e.g., see references 7, 38, 39). Each line had an individual
pattern of recognition of the peptides, which was consistent
during the propagation ofthe lines, although recognition ofless
dominant peptides was somewhat erratic, either because of
clonal loss or because the high basal rate of cell proliferation
caused an unfavorably high background (Fig. 2).
Line 1 had the most complex pattern of peptide recogni-
tion. Peptides Hy75-94 and Hy32 1-340 were strongly recog-
nized in all experiments. Two other peptides, Hy3O-49 and
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Figure 1. Responses of anti-y subunit CD4+ T cell lines propagated
from four MG patients to PHA (10 Mg/ml), Sy pool (5 Mug/ml), and
purified FBAChR (5 Mg/ml) measured in 2-d microproliferation as-
says. Values are incorporation of [3H~thymidine by the T cells (aver-
age of triplicate determinations±SD). The responses to y pool and
FBAChR of line 4 were assessed in two different experiments and the
corresponding values of [3H]thymidine incorporation induced by
PHA are reported as positive controls. All the lines responded vigor-
ously both toy pool and FBAChR. Basal [3H]thymidine incorpora-
tion of the blasts in the presence of APC only was subtracted and was
as follows: line 1: 1,9701,063; line 2: 8,745±186; line 3:
15,032±2,707; line 4, first experiment: 9,540±506; second experi-
ment: 28,873±1,800. Asterisks indicate responses significantly higher
than the unstimulated proliferative rate of the blasts (* * ** P < 0.001,
***P < 0.005, **P < 0.01). See text for experimental details.
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H'y297-312, were consistently recognized to a lesser extent,
and recognition of Hy297-312 decreased during propagation
of the line. Peptides Hy135-154 and Hy470-489 elicited a
small but significant increase of T cell proliferation in some
experiments. Line 2 strongly recognized peptide Hy75-94 in
all experiments and peptide Hy470-489 in one experiment.
Line 3 recognized two sequence segments, peptide Hy75-94
and the overlapping peptides Hy321-340 and Hy336-355 in
all experiments, and two other peptides (Hy135-154 and
HWy411-430) in two experiments. Line 4 consistently, strongly
recognized one peptide, Hy321-340.
Lack ofdetectable response to y subunit synthetic sequences
of unselected blood CD4+ cells. We attempted assessment of
the faithfulness of the epitope repertoire of the long-term cell
lines compared with that ofthe unselected blood CD4+ cells by
directly testing in microproliferation assay the CD4+-enriched
population from the blood of patients 3 and 4. As expected
from patients suffering from mild symptoms (40, 41), the
CD4+-enriched cells did not respond detectably to any y sub-
unit peptide.
Response to y subunit synthetic sequences of CD4+ lines
from healthy controls. We investigated the response to the indi-
vidual peptides ofT cell lines that could be propagated for a few
weeks from three normal subjects. Line from control 5 did not
recognize any peptide detectably (data not shown) whereas
lines from controls 3 and 4 responded to several peptides (see
Fig. 4). Control line 3 was tested three times: it clearly recog-
nized several peptides (Hy75-94, Hy297-312, Hy321-340
and the overlapping peptides Hy470-489 and Hy476-495)
only during the first experiment (Fig. 3 A). Control line 4 had a
slow rate of growth and could be tested only once (Fig. 3 B).
Peptides Hy 165-184 and Hy476-495 were clearly recognized.
The overlapping peptides, Hy 120-139 and Hy 135-154, elic-
ited a low but significant response.
Similarities of the y subunit epitope-forming sequences
with sequences of unrelated proteins. Several peptides recog-
nized by the CD4+ lines had strong similarities with sequence
regions from unrelated proteins, as summarized in Table III,
where the y subunit peptide epitopes are aligned on the unre-
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Figure 2. Response of anti-y subunit CD4+ T cell lines from MG patients to the individual synthetic peptides forming the y Pool ( 10 Atg/ml)
measured in 2-d microproliferation assays. The first test was carried out after a satisfactory enrichment in y pool-specific T cell was reached,
indicated by reactivity to the y pool as high or higher than the response to PHA (after two or three cycles of stimulation with the antigen). A,
B, C, and D refer to successive tests, carried out at intervals of > 1-2 wk. The asterisks indicate responses significantly higher than the unstimu-
lated proliferative rate of blasts in the presence of APC only, with or without 10 ,tg/ml of the unrelated peptide E73 (****P < 0.001, ***P
< 0.005, **P < 0.01, *P < 0.025). See text for experimental details.















vatively substituted are indicated with boldfaced characters. Of
the sequence pairs containing substantial similarities, we se-
lected those containing sequence segments 10-16 residues
long, with > 75% amino acids being identical or conservatively
substituted. Insertions/deletions introduced to optimize the
alignment were counted as extra positions. A length of 10-16
residues was chosen as a conservative compromise between the
minimal length found in functional assays for class I-restricted
T epitopes (5-7 residues [42, 43]), and the length of the se-
quences found to bind to MHC molecules, 8-9 residues for
class I-presented peptides (44-47), and somewhat longer se-
quence segments for class II-presented peptides (48, 49).
Discussion
We have identified here sequence segments of the human y
subunit that form epitopes recognized by autoimmune Th cell
lines specific for embryonic AChR, obtained fromMG patients
of different HLA-DR type. Other epitopes may have gone un-
detected because of the small size of the patient population,
because of poor representation by our peptide panel, or be-
cause of selection of clones recognizing epitopes within pep-
tides better processed into the relevant epitope and/or better
able to bind the DR-restricting elements. Within these limita-
tions, our approach permitted unambiguous identification of
several epitopes.
Fig. 4 summarizes the sequence regions of the y subunit-
containing epitopes recognized by the MG lines and the HLA-
DR haplotype ofthe patients. The specificity ofthe lines for the
epitope peptides was stable and was not a reflection ofthe dura-
tion of the culture because the pattern of peptide recognition
remained consistent during propagation ofthe lines. Although
some peptide sequences were recognized only by one line, as
might be expected for Th cells ofdifferent HLA-DR haplotype,
a substantial overlap existed in the epitope repertoires of the
lines, and the sequences H-y75-94 and Hy32 1-340 were recog-
nized by three lines. Immunodominant regions were previ-
ously identified along the AChR a subunit sequence, contain-
ing epitopes recognized by most MG patients irrespective of
their HLA-DR haplotype ( 13, 41 ). In multiple sclerosis a pep-
tide corresponding to aminoacids 87-106 of the myelin basic
protein is frequently recognized by T cells of these patients: the
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1 Figure 3. Response of short-
term T cell lines obtained
from two'healthy controls to
the individual synthetic pep-
tides forming the y pool (10
,gg/ml). Asterisks indicate
responses significantly higher
than the unstimulated prolif-
erative rate of blasts in the
presence of APC only, with
or without 10 &g/ml ofthe
unrelated peptide E73
(****P < 0.001, ***P
<0.005, **P<().(1, *P
< 0.025). See text for experi-
mental details.


























Table III. Sequence Regions ofthe Human y Subunit Forming T Epitopes: Similarities with Sequences of Unrelated Proteins*
Protein containing a similar sequence
T epitope Sequences (database accession #)
,y30-49 NVSLKLTLTNLISLNEREEA
NVDKKLLKKALEQLNEREKQ RNA polymerase sigma-E factor precursor. Bacillus subtilis (RPSE$BACSUW)
NVSLKLTLTNLISLNEREEA
SVSLPLTLKELI-----EEL T cell activation protein P600. Mouse (p600$MOUSE*).
NVSLKLTLTNLISLNEREEA
IVSLLTFLNVLITLNNKYKH Early E3 22.2 kD protein. Adenovirus type 1 (E322$ADEClI).
NVSLKLTLTNLISLNEREEA
NVLQKLYISMLISLQILLIM NADH-Ubiquinone Oxidoreductase Chain 4. Mouse (NU4M$MOUSE)*.
y135-154 FPFDWQNCSLIFQSQTYSTN
TWFDWNNQSLPYHSQKLRLE B cell receptor CD22 precursor. Human (CD22$HUMANt).
y336-355 EVAL-CLPRSELLFQQWQRQG
RVAVNHLPR-ELIFQVWQRSW VPX protein. Human immunodeficiency virus type 2 (VPX$HIV2Dt).
EVALCLPRSELLFQQWQRQG
EVGLKGERSELLLSEKVVDA Erythroid differentiation factor precursor. Human (A30884)t.
y411-430 QAAPAIQACVE--ACNLIACAR
QAAPAIQNDVEMAAVNLSVFVD Ribonucleoside-diphosphate reductase. Human cytomegalovirus (RIR1$HCMVA$).
QAAPAIQACVEACNLIACAR
QAAPDLQENVHATVLIEETM Probable RNA-directed RNA polymerase. Tobacco rattle virus (194K$TRVSYt).
Sy476-495 NRVPALPF-PGDPRPYLPSP-D
PN-LLAL-FAPRDPIPYLP-PLE 70K Ul small nuclear ribonucleoprotein. Human (RUl7$HUMANt).
NRVPA-LPFPGDPRPYL---PSP
TQ-PPAPVG-PGDPDVYLKGVPSA DNA-binding protein. Herpes simplex virus (type 1, strain 17) (DNB$HSV1 lt).
* For all sequence segments of the human AChR y subunit identified here as forming T epitopes (y3O-49, y60-79, y75-94, y 120-139, y 135-
154, y 165-184, 'y297-3 12, ey321-340, y336-3355, y411-430, y470-489, and y476-495) we searched for sequence similarities with the proteins
in the databases PIR 29 and Swiss-Prot 19. The table reports only the T epitope sequence regions for which similarities with unrelated proteins
were found. See text for further details. t From Swiss-Prot 19. § From PIR 29.
use of long-term myelin basic protein-specific T cell lines al-
lowed identification ofa core sequence (residues 89-99) recog-
nized in the context of four different HLA-DR types (50).
Because T epitopes can be as small as 5-7 residues (42, 43), the
sequence regions identified here may contain several nested T
epitopes, as it occurs in sequence regions of similar or even
shorter length from other protein antigens (51-54). Alterna-
tively, one or more of these sequence segments may contain a
single immunodominant T epitope, recognized within several
or any MHC-class II haplotype as described for T epitopes on
other proteins (39, 55). The Th immunodominance of the
regions identified here may be due to easier cleavage and pro-
cessing, since they are probably located on the AChR surface
(see below), and to the ability of human DR molecules to
interact with unrelated peptides (56, 57).
A potential caveat to the use oflong-term T cell lines is that
selective clonal loss/enrichment may bias their repertoire.
Comparison of the repertoire of the lines with that of unse-
lected blood CD4 + cells could not be done because, due to the
paucity of AChR-specific CD4+ cells in the blood ofMG pa-
tients (7), testing of blood CD4+ cells with AChR sequences is
successful only in acutely, severely affected patients, never in
the moderately affected patients from which the repetitive
bleedings necessary for establishment of the lines can be ob-
tained (7, 13). Accordingly, unselected CD4+ cells from pa-
tients 3 and 4 did not detectably recognize any y subunit se-
quence. In favor ofgood concordance ofthe epitope repertoires
of unselected CD4 + cells and of long-term Th lines is the find-
ing that the sequence regions of the AChR a subunit recog-
nized by unselected CD4+ cells of severely affected MG pa-
tients are very similar to those recognized by long-term AChR-
specific lines propagated from moderately affected patients by
the use of a peptide pool corresponding to the a subunit se-
quence (41) .
Patients 2 and 4 were donors ofcells used to establish anti-a
subunit CD4+ T cell lines (13). Comparison of the four T
immunodominant regions of the a subunit sequence (Ha32-
67, Ha 101-120, Ha304-337, Ha419-437: the latter segment
corresponds to the carboxyl terminus of the human a subunit)
(13, 41) with those identified here on the y subunit sequence,
reveals a similar distribution of the T epitope segments along
the a and the y subunit sequence. Four y subunit epitope pep-
tides (Hy3O-49, Hy75-94, HFy321-355, and Hy470-489)
have a sequence location similar to that of the immunodomi-
nant a subunit, although these segments are highly divergent in
the a and the y subunit (Fig. 4). In both a and -y subunits the
immunodominant segments are within regions predicted to
form non-transmembrane parts of the AChR molecule, and
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because ofthe presence ofseveral charged and hydrophilic resi-
dues they may be exposed on the AChR surface. All but one T
epitope peptides on the y subunit identified here are within
sequence segments proposed to form surface domains of the
AChR, either extracellular (sequences 30-49, 75-94, 135-154,
and possibly 470-489) or cytoplasmic (sequences 321-355
and 411-430) (14), suggesting that T epitopes might easily
originate from surface regions of a protein.
Th cells against autoantigens, including the AChR, exist in
normal subjects (e.g., references 9, 58). A CD4' T line specific
for the 6 subunit ofhuman muscle AChR was propagated, for a
short time only, from a normal subject (12), and AChR-
specific T cell clones could be obtained from healthy humans
by stimulation with a biosynthetic fragment ofmouse AChR a
subunit, but less frequently than from MG patients (59), sug-
gesting that potentially autoreactive T cells exist in the normal
population, but in lesser amounts or binding the antigen less
efficiently than bona fide autoimmune T cells. In agreement
with those results, -y pool-specific CD4' cell lines could be
propagated from three controls, but only for a short time. Con-
trol line 5 responded detectably to the y pool, but not to any
individual peptide (not shown), suggesting that CD4' T cells
specific for AChR y subunit sequences existed in this subject,
but they interacted with several y epitopes with too low affinity
for any one peptide epitope to be clearly recognized in vitro.
Control line 3 had a pattern of peptide recognition similar to
that of MG line 1, which had the same DR haplotype: both
lines recognized the "immunodominant" peptides Hy75-94
and Hy321-340 and peptides H-y297-312 and Hy470-489
(Fig. 3). The latter peptides were not recognized by any other
line and may therefore be restricted by the DR5 molecule,
which was only expressed by MG line 1 and control line 3. Of
the peptide recognized by control line 5, Hy 135-154 was also
recognized by MG lines 1 and 3 (Fig. 4). Autoreactive T cells
have been demonstrated in many experimental systems where
the host does not normally develop an autoimmune disease
(60), including experimental autoimmune myasthenia gravis
(61, 62). The presence of CD4+ cells reactive to self antigens
does not indicate a failure oftolerance because the autoreactive
cells clonally deleted during maturation within the thymus are
probably those with optimal (highest) affinity for the self anti-
gen/MHC complex (for review see reference 60). Autoreac-
tive T cells with low affinity antigen receptor may escape clonal
deletion and never be activated at the periphery because ofthe
low affinity of their T cell receptors (60, 63).
Immunological cross-reactivity between viral or bacterial
antigens and normal protein constituents of the host may be
involved in development of autoimmune diseases, including
MG, because microbial proteins and human autoantigens con-
tain identical or similar sequence segments, which may form
cross-reacting epitopes (27). Some T epitope sequences of the
AChR -y subunit resembled sequence regions ofother proteins,
frequently of microbial origin (Table III). This may indicate
that molecular mimicry with microbial proteins is indeed in-
volved in autoimmune responses or that some of our peptides
were recognized as a result of cross-reactivity, facilitated by the
higher concentration of peptide in vitro compared with the in
vivo conditions, of T cells sensitized against common viruses
and bacteria. In support of the latter possibility the sequence
Hy476-495, recognized by two control lines (Figs. 3 and 4),
has strong similarities with a protein component ofthe Herpes
simplex virus, which is very common in humans. The relative
high frequency of sequence similarities of AChR sequence re-
gions with unrelated proteins is not surprising because certain
short amino acid sequences (3-5 residues), presumably corre-
sponding to specific tridimensional structural motifs, occur in
the sequence of known proteins with a much higher frequency
than statistically expected, and they have a propensity to clus-
ter together, making it likely and indeed frequent that frag-
ments of alien proteins up to 7-18 residues in length (i.e.,
enough for T epitope formation [43-49]) share substantial se-
quence similarities with fragments of self proteins (64). Fur-
ther "filters" must exist in the immune system to avoid a wide-
spread occurrence of autoimmune phenomena. Among them,
the necessity for an alien sequence resembling a self protein to
be processed and presented, which may not occur if it is not on
the protein surface, or flanked by residues incompatible with
processing (65) and the availability of a potentially reactive T
clone, which may have been deleted during the thymic educa-
tion of the T cells. The two immunodominant regions Hy75-
94 and Hy321-340 did not yield any sequence similarities with
unrelated known proteins.
Fig. 4 depicts alignments of the T epitope sequence seg-
ments of the -y subunit with the homologous segments of the
other known subunits of human muscle AChR and of the y
and E subunits of bovine muscle AChR. The bovine E subunit
substitutes for the still unknown sequence of the human E sub-
unit ( 14). Some T epitope peptide sequences are highly di-
verged (e.g., Hy321-355 and Hy 411-430) and it is unlikely
that the corresponding T cells cross-react with homologous seg-
ments of other AChR subunits. Others contain stretches of
residues conserved or conservatively substituted in other
AChR subunits (e.g., the sequences TLTNLISLN, FPFD-
WQNCSL, SLKLTLLNILSNE, FPFDWQNCSLVF, and
VVVLNVSLRSP, identical or almost identical in the y and
E subunits) and may have stimulated and propagated T
cells non--y subunit specific. This may explain the reported
cross-reactivity of line 1 with both embryonic and adult
AChRs (19).
The preferential or unique response of the CD4+ cell lines
to embryonic AChR (19) and the finding that several epitopes
they recognize are within sequence regions highly diverged be-
tween the y and the other AChR subunits prove that these T
cells are specific for embryonic AChR. Because embryonic
AChR is not expressed by adult innervated muscle, this finding
lends credence to the proposed origin ofthe anti-AChR sensiti-
zation in MG within the thymus (20), which expresses an
AChR similar or identical to embryonic muscle AChR, con-
taining a y subunit (18) . Because the thymus AChR also con-
tains a, ,B, and 6 subunits (18), T cells sensitized against epi-
topes formed by subunit present also in the more abundant
muscle AChR may be preferentially expanded. Anti-y Th cells,
as the disease progresses, may become a small fraction of the
anti-AChR Th population and have a marginal role in the pro-
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Figure 4. Sequence segments recognized by the four T cell lines and their HLA-DR haplotypes. Peptides that elicited a strong response are indi-
cated as densely hatched segments, peptides that elicited a lower response are indicated as increasingly lighter hatched segments. The sequence
segments ofthe -y subunit containing Th epitopes are reported and are aligned with the corresponding segments ofthe other known human AChR
subunits and with the bovine AChR -y and e subunit, which substitutes for the still unknown sequence of the human e subunit.
duction of pathogenic anti-AChR antibodies. Still, their exis-
tence suggests a nonmuscle origin of the anti-AChR response.
Although the autoimmune Th response against AChR in
MG is polyclonal, a limited sequence of at least two ofAChR
subunits, the a ( 13, 49) and the y subunits, seems to be in-
volved in Th cell sensitization. This may allow development of
specific immunosuppressive procedures, based on the use of
synthetic peptides analogues, able to tightly bind to the class II
molecules but unable to bind the T cell receptor ofthe autoim-
mune T cell and competing with the pathogenetic T epitope for
their presentation, as it was successfully done in experimental
autoimmune encephalomyelitis (66-68). Availability of hu-
man autoimmune anti-AChR CD4' T cell lines and knowl-
edge ofthe epitopes recognized are necessary steps towards this
goal.
Acknowledgments
Supported by the National Institute of Neurological Disorders and
Stroke grant NS 29919 (B. M. Conti-Tronconi) and a grant from the
Muscular Dystrophy Association (MDA) (B. M. Conti-Tronconi).
M. P. Protti was the recipient of the MDA Sidney Blackmer Fellow-
ship. A. A. Manfredi was a recipient of a MDA Postdoctoral Fellow-
ship.
References
1. Lindstrom, J. D., D. Shelton, and Y. Fujii. 1988. Myasthenia gravis. Adv.
Immunol. 42:233-284.
2. Drachman, D. 1983. Myasthenia gravis: immunobiology of a receptor dis-
order. Trends Neurosci. 6:446-448.
3. Engel, A. G. 1984. Myasthenia gravis and myasthenic syndromes. Ann.
Neurol. 16:519-534.
4. Schonbeck, S., S. Chrestel, and R. Hohlfeld. 1990. Myasthenia gravis: pro-
totype ofthe antireceptor autoimmune diseases. Int. Rev. Neurobiol. 32:175-20 1.
5. Hohlfeld, R., K. V. Toyka, K. Heininger, H. Grosse-Wilde, and I. Kalies.
1984. Autoimmune human T-lymphocytes specific for acetylcholine receptor.
Nature (Lond.). 310:244-246.
6. Hohlfeld, R., K. V. Toyka, S. J. Tzartos, W. Carson, and B. M. Conti-Tron-
coni. 1987. Human T helper lymphocytes in myasthenia gravis recognize the
nicotinic receptor a subunit. Proc. Natl. Acad. Sci. USA. 84:5379-5383.
7. Protti, M. P., A. A. Manfredi, C. Straub, X. Wu, J. F. Howard, and B. M.
Conti-Tronconi. 1990. Use of synthetic peptides to establish anti-human acetyl-
choline receptor CD4+ cell lines from myasthenia gravis patients. J. Immunol.
144:1711-1720.
8. Melms, A., S. Chrestel, B. C. G. Shalke, H. Wekerle, A. Mauron, M. Balli-
vet, and T. Barkas. 1989. Autoimmune T lymphocytes in myasthenia gravis.
Determination of target epitopes using T lines and recombinant products of the
mouse nicotinic acetylcholine receptor gene. J. Clin. Invest. 83:285-289.
9. Harcourt, G. C., N. Sommer, J. Rothbard, H. N. A. Willcox, and J. New-
som-Davis. 1988. A juxta-membrane epitope on the human acetylcholine recep-
tor recognized by T cells in myasthenia gravis. J. Clin. Invest. 82:1295-1330.
10. Hohlfeld, R., I. Kalies, B. Kohleisen, K. Heininger, B. M. Conti-Tronconi,
and K. V. Toyka. 1986. Myasthenia gravis: stimulation of antireceptor autoanti-
bodies by autoreactive T-cell lines. Neurology. 36:618-621.
11. Hohlfeld, R., B. M. Conti-Tronconi, I. Kalies, J. Bertrams, and K. V.
Toyka. 1985. Genetic restriction ofautoreactive acetylcholine receptor-specific T
lymphocytes in myasthenia gravis. J. Immunol. 135:2393-2399.
12. Protti, M. P., A. A. Manfredi, X. D. Wu, L. Moiola, J. F. Howard, Jr., and
B. M. Conti-Tronconi. 1991. Myasthenia gravis: T epitopes of the 6 subunit of
human muscle acetylcholine receptor. J. Immunol. 146:2253-2261.
13. Protti, M. P., A. A. Manfredi, C. Straub, J. F. Howard, Jr., and B. M.
Conti-Tronconi. 1990. Immunodominant regions for T helper sensitization on
the human nicotinic receptor a subunit in myasthenia gravis. Proc. Natl. Acad.
Sci. USA 87:7792-7796.
14. McCarthy M. P., J. P. Earnest, E. F. Young, S. Choe, and R. M. Stroud.
1986. The molecular neurobiology of the acetylcholine receptor. Annu. Rev.
Neurosci. 9:383-414.
15. Mishina, M., T. Takai, K. Imoto, M. Noda, T. Takahashi, S. Numa, C.
Methfessel, and B. Sakmann. 1986. Molecular distinction between fetal and adult
forms of muscle acetylcholine receptor. Nature (Lond.). 321:406-41 1.
16. Witzemann, V., B. Barg, Y. Nishikawa, B. Sakmann, and S. Numa. 1987.
Differential regulation of muscle acetylcholine receptor y- and E-subunit
mRNAs. FEBS (Fed. Eur. Biochem. Soc.) Lett. 223:104-112.
17. Gu, Y., and Z. W. Hall. 1988. Immunological evidence for a change in
subunits of the acetylcholine receptor in developing and denervated rat muscle.
Neuron. 1:117-125.
18. Nelson, S., and B. M. Conti-Tronconi. 1990. Adult thymus expresses an
embryonic nicotinic acetylcholine receptor-like protein. J. Neuroimmunol.
29:81-92.
19. Protti, M. P., A. A. Manfredi, J. F. Howard, Jr., and B. M. Conti-Tron-
coni. 1991. T cells in myasthenia gravis specific for embryonic acetylcholine
receptor. Neurology. 41:1809-1814.
20. Wekerle H., R. Hohlfeld, U.-P. Ketelsen, J. Kalden, and I. Kalies. 1981.
Thymic myogenesis, T lymphocytes and the pathogenesis of myasthenia gravis.
Ann. NYAcad. Sci. 377:455-476.
21. Weinberg, C. B., and Z. W. Hall. 1979. Antibodies from patients with
myasthenia gravis recognize determinants unique to extrajunctional acetylcho-
line receptors. Proc. Natl. Acad. Sci. USA. 76:504-508.
22. Vincent, A., P. J. Whiting, M. Schluep, F. Heidenreich, B. Lang, A. Rob-
erts, and N. Wilcox. 1987. Antibody heterogeneity and specificity in myasthenia
gravis. Ann. NYAcad. Sci. 505:106-120.
23. Schuetze, S. M., S. Vicini, and Z. W. Hall. 1985. Myasthenic serum
selectively blocks acetylcholine receptors with long channel open times at develop-
ing rat endplates. Proc. Nadl. Acad. Sci. USA. 782:2533-2537.
24. Li, A., A. Papatestas, A. Kark, R. S. Osserman, and K. Osserman. 1971.
An histologic reappraisal ofthe thymus in myasthenia gravis. A correlative study
thymic pathology and response to thymectomy. Arch. Pathol. 91:55-61.
25. Lisak, R. P., A. I. Levinson, B. Zweiman, and M. R. Kornstein. 1986.
Antibodies to acetylcholine receptor and tetanus toxoid: in vitro synthesis by
thymic lymphocytes. J. Immunol. 136:1221-1225.
26. Olanow, C. W., A. S. Wechsler, M. Sirotkin-Roses, J. Stajich, and A. D.
Roses. 1987. Thymectomy as primary therapy in myasthenia gravis. Ann. NY
Acad. Sci. 505:595-606.
27. Oldstone, M. B. A. 1987. Molecular mimicry and autoimmune disease.
Cell. 50:819-820.
28. Sanders, D. B., J. F. Howard, Jr., T. R. Johns, and J. F. Campa. 1979.
High-dose daily prednisone therapy in myasthenia gravis. In Plasmapheresis and
Immunobiology of Myasthenia Gravis. Vol. 27. P. C. Dau, editor. Houghton-
Mifflin Professional Publishers, Boston. 289-306.
29. Lindstrom, J. 1977. An assay for antibodies to human acetylcholine recep-
tor in serum from patients with myasthenia gravis. Clin. Immunol. Immuno-
pathol. 7:36-42.
30. Shibahara, S., T. Kubo, H. J. Perski, H. Takahashi, M. Noda, and S.
Numa. 1985. Cloning and sequence analysis of genomic DNA encoding y sub-
unit precursor of muscle acetylcholine receptor. Eur. J. Biochem. 146:15-21.
31. Hohlfeld, R., M. Michels, H. Tesch, A. Fahsbender, K. Heininger, B. M.
Conti-Tronconi, and K. M. Toyka. 1986. Epstein-Barr virus-transformed B cells
can present acetylcholine receptor to autologous autoreactive T cells. Immunol.
Lett. 12:171-174.
32. Houghten, R. A. 1985. General method for the rapid solid phase synthesis
of large numbers of peptides: specificity of antigen-antibody interaction at the
level of individual amino acids. Proc. Natl. Acad. Sci. USA. 82:5131-5135.
33. Heinrickson, R. L., and S. C. Meredith. 1984. Amino acid analysis by
reverse phase high performance liquid chromatography; precolumn derivatiza-
tion with phenylisothiocyanate. Anal. Biochem. 136:65-74.
34. Gotti, C., B. M. Conti-Tronconi, and M. A. Raftery. 1982. Mammalian
muscle acetylcholine receptor purification and characterization. Biochemistry.
21:3148-3154.
35. Gorin, M. B., S. Yancey, J. Cline, J.-P. Revel, and J. Horwitz. 1984. The
major intrinsic protein (MIP) of the bovine lens fiber membrane: characteriza-
tion and structure based on cDNA cloning. Cell. 39:49-55.
36. Brutlag, D. L., J. P. Dautricort, S. Manlik, and J. Relph. 1990. Sensitive
similarity searches of biological sequence databases. Comput. Appl. Biosci.
6:237-245.
37. Takai, T., M. Noda, Y. Furutani, H. Takahashi, M. Notake, S. Shimizu,
T. Kayano, T. Tanabe, K. Tanaka, T. Hirose, et al. 1984. Primary structure of y
subunit precursor of calf muscle acetylcholine receptor deduced from the cDNA
sequence. Eur: J. Biochem. 143:109-115.
38. Ellerman, K. E., J. M. Powers, and S. W. Brostoff. 1988. A suppressor
T-lymphocyte cell line for autoimmune encephalomyelitis. Nature. (Lond.).
33 1:265-267.
39. Sinigaglia, F., M. Guttinger, J. Kilgus, D. M. Doran, H. Matile, H. Et-
linger, A. Trzeciak, A. Gillessen, and J. R. L. Pink. 1988. A malaria T-cell epitope
recognized in association with most mouse and human MHC Class II molecules.
Nature (Lond.). 336:778-780.
40. Protti, M. P., A. A. Manfredi, C. Straub, J. Howard, and B. M. Conti-
Tronconi. 1990. CD4+ T cell response to human acetylcholine receptor a subunit
correlates with myasthenia gravis severity. A study with synthetic peptides. J.
Immunol. 144:1276-1281.
41. Manfredi, A. A., M. P. Protti, X. D. Wu, J. F. Howard, Jr., and B. M.
1566 Protti, Manfredi, Wu, Moiola, Dalton, Howard, and Conti-Tronconi
Conti-Tronconi. 1992. CD4' T epitope repertoire on the human acetylcholine
receptor a subunit in severe myasthenia gravis. A study with synthetic peptides.
Neurology. 42:1092-1 100.
42. Livingston, A. M., and C. Garrison-Fathman. 1987. The structure of
T-cell epitopes. Annu. Rev. Immunol. 5:477-501.
43. Reddehase, M. J., J. B. Rothbard, and U. H. Koszinowski 1989. A penta-
peptide as minimal antigenic determinant for MHC class I-restricted T lympho-
cytes. Nature (Lond.). 337:651-652.
44. Van Bleek, G. M., and S. G. Nathenson. 1990. Isolation of an endoge-
nously processed immunodominant viral peptide from the class I H-2Kb mole-
cule. Nature (Lond.). 348:213-218.
45. Falk, K., 0. Rotzshke, K. Deres, J. Metzger, G. Jung, and H.-G. Rammen-
see. 1991. Identification of naturally processed viral nonapeptides allows their
quantification in infected cells and suggests an allele-specific T cell epitope fore-
cast. J. Exp. Med. 174:425-433.
46. Madden, D. R., J. C. Gorga, J. L. Strominger, and D. C. Wiley. 1991. The
structure of HLA-B27 reveals nonamer self-peptides bound in an extended con-
formation. Nature (Lond.). 353:321-326.
47. Jardetzky, T. S., W. S. Lane, R. A. Robinson, D. R. Madden, and D. C.
Wiley. 1991. Identification of self peptides bound to purified HLA-B27. Nature
(Lond.). 353:326-329.
48. Demotz, S., H. M. Grey, E. Appella, and A. Sette. 1989. Characterization
of a naturally processed MHC class II-restricted T-cell determinant of hen egg
lysozyme. Nature (Lond.). 342:682-684.
49. Rudensky, A. Y., P. Preston-Hurlbut, S.-C. Hong, A. Barlow, and C. A.
Janeway, Jr. 1991. Sequence analysis of peptides bound to MHC class II mole-
cules. Nature (Lond.). 353:622-624.
50. Martin, R., M. D. Howell, D. Jaraquemada, M. Flerlage, J. Richert, S.
Brostoff, E. 0. Long, D. E. MacFarlin, and H. F. McFarland. 1991. A myelin
basic protein peptide is recognized by cytotoxic T cells in the context of four
HLA-DR types associated with multiple sclerosis. J. Exp. Med. 173:19-24.
51. Lambert, L. E., and E. R. Unanue. 1989. Analysis of the interaction of
peptide hen egg white lysozyme (34-45) with the I-Ak molecule. J. Immunol.
143:802-807.
52. Nicholas, J. A., M. E. Levely, M. A. Mitchell, and C. W. Smith. 1989. A
16-amino acid peptide of respiratory syncytial virus 1A protein contains two
overlapping T cell-stimulating sites distinguishable by class II MHC restriction
elements. J. Immunol. 143:2790-2796.
53. Brett, S. J., K. B. Cease, C.-A. S. Ouyang, and J. A. Berzofsky. 1989.
Influences of antigen processing on the expression of the T cell repertoire evi-
dence for MHC-specific hindering structures on the products of processing. J.
Immunol. 143:771-779.
54. Sakai, K., A. A. Sinha, D. J. Mitchell, S. S. Zamvil, J. B. Rothbard, H. 0.
McDevitt, and L. Steinman. 1988. Involvement of distinct murine T-cell recep-
tors in the autoimmune encephalitogenic response to inbred epitopes of myelin
basic protein. Proc. Natl. Acad. Sci. USA. 85:8608-8612.
55. Clerici, M., N. I. Stocks, R. A. Zajac, R. N. Boswel, D. C. Berustein, D. L.
Mann, G. M. Sheares, and J. A. Berzofsky. 1989. Interleukin-2 production used
to detect antigenic peptide recognition by T-helper lymphocytes from asymptom-
atic HIV-seropositive individuals. Nature (Lond.). 339:383-385.
56. Sette, A., S. Buus, S. Colon, C. Miles, and H. M. Grey. 1989. Structural
analysis of peptides capable ofbinding to more than one Ia antigen. J. Immunol.
142:35-40.
57. Panina-Bordignon, P., A. Tan, A. Termijtelen, S. Demotz, G. Corradin,
and A. Lanzavecchia. 1989. University immunogenic T cell epitopes: promiscu-
ous binding to human MHC class II and promiscuous recognition by T cells. Eur.
J. Immunol. 19:2237-2242.
58. Pette, M., K. Fujita, B. Kitze, J. N. Whitaker, E. Albert, L. Kappos, and H.
Wekerle. 1990. Myelin myelin basic protein-specific T lymphocyte lines from
multiple sclerosis patients and healthy individuals. Neurology. 40:1770-1776.
59. Zhang, Y., M. Schluep, S. Frutiger, G. J. Hughes, M. Jaenner, A. Steek,
and T. Barkas. 1990. Immunological heterogeneity of autoreactive T lympho-
cytes against the nicotinic acetylcholine receptor in myasthenic patients. Eur. J.
Immunol. 20:2577-2583.
60. Gammon, G., and E. E. Sercarz. 1990. Does the presence ofself-reactive T
cells indicate the breakdown of tolerance? Clin. Immunol. Immunopathol.
56:287-297.
61. Bellone, M., N. Ostlie, S. Lei, and B. M. Conti-Tronconi. 1991. Experi-
mental myasthenia gravis in congenic mice. Sequence mapping and H-2 restric-
tion of T helper epitopes on the a subunits of Torpedo californica and murine
acetylcholine receptors. Eur. J. Immunol. 21:2302-2310.
62. Granato, D. A., B. W. Fulpius, and J. F. Moody. 1986. Experimental
myasthenia in Balb/c mice immunized with rat acetylcholine receptor from rat
denervated muscle. Proc. Natl. Acad. Sci. USA. 73:2872-2876.
63. Gammon, G., and E. E. Sercarz. 1989. How some T-cells escape tolerance
induction. Nature (Lond.). 342:183-185.
64. Ohno, S. 1991. Many peptide fragments ofalien antigens are homologous
with host proteins, thus canalizing T-cell responses. Proc. Natl. Acad. Sci. USA.
88:3065-3068.
65. Del Val, M., H.-J. Schlicht, T. Ruppert, M. J. Reddehase, and U. H.
Koszinowski. 1991. Efficient processing ofan antigenic sequence for presentation
by MHC class I molecules depends on its neighboring residues in the protein.
Cell. 66:1145-1153.
66. Sakai, K., S. S. Zamvill, D. J. Mitchell, S. Hodgkinson, J. B. Rothbard,
and L. Steinman. 1989. Prevention ofexperimental encephalomyelitis with pep-
tides that block interaction of T cells with major histocompatibility complex
proteins. Proc. Natl. Acad. Sci. USA. 86:9470-9474.
67. Wraith, D. C., D. E. Smilek, D. J. Mitchell, L. Steinman, and H. 0.
McDevitt. 1989. Antigen recognition in autoimmune encephalomyelitis and the
potential for peptide-mediated immunotherapy. Cell. 59:247-255.
68. Gauam, A. M., and P. Glynn. 1990. Competition between foreign and self
proteins in antigen presentation. Ovalbumin can inhibit activation of myelin
basic protein-specific T cells. J. Immunol. 144:1177-1180.
69. Noreen, H. J., M. L. Davidson, J. McCullough, F. H. Bach, and M. Segall.
1989. HLA Class Ii typing by restriction fragment length polymorphism (RFLP)
in unrelated bone marrow transplant patients. Transplant. Proc. 21:2968-2970.
70. National Institute of Health Transplantation and Immunology Branch
Staff. 1979. NIA lymphocyte microcytotoxicity technique T.39. In Manual of
Tissue Typing Techniques. NIH Publication No. 80-545. T. Ray, Editor. U.S.
Dept. of Health, Education, and Welfare, Washington, DC. 39-40.
T Epitopes in Myasthenia Gravis 1567
